MX2024001277A - Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1). - Google Patents

Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).

Info

Publication number
MX2024001277A
MX2024001277A MX2024001277A MX2024001277A MX2024001277A MX 2024001277 A MX2024001277 A MX 2024001277A MX 2024001277 A MX2024001277 A MX 2024001277A MX 2024001277 A MX2024001277 A MX 2024001277A MX 2024001277 A MX2024001277 A MX 2024001277A
Authority
MX
Mexico
Prior art keywords
klrg1
cells
methods
subject
expressing
Prior art date
Application number
MX2024001277A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Evan Thompson
Stefano Vincenzo Gulla
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of MX2024001277A publication Critical patent/MX2024001277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024001277A 2021-07-26 2022-07-26 Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1). MX2024001277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225828P 2021-07-26 2021-07-26
US202263308222P 2022-02-09 2022-02-09
PCT/US2022/038310 WO2023009498A1 (en) 2021-07-26 2022-07-26 Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Publications (1)

Publication Number Publication Date
MX2024001277A true MX2024001277A (es) 2024-02-15

Family

ID=85087207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001277A MX2024001277A (es) 2021-07-26 2022-07-26 Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).

Country Status (7)

Country Link
US (1) US20250101112A1 (enExample)
EP (1) EP4377346A1 (enExample)
JP (1) JP2024528877A (enExample)
AU (1) AU2022320627A1 (enExample)
CA (1) CA3227742A1 (enExample)
MX (1) MX2024001277A (enExample)
WO (1) WO2023009498A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AU2017326003A1 (en) 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
MY198590A (en) * 2018-08-29 2023-09-07 United Biopharma Inc Afucosylated antibodies and manufacture thereof
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).

Also Published As

Publication number Publication date
US20250101112A1 (en) 2025-03-27
WO2023009498A1 (en) 2023-02-02
CA3227742A1 (en) 2023-02-02
AU2022320627A1 (en) 2024-02-08
JP2024528877A (ja) 2024-08-01
EP4377346A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
Nersesian et al. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MY205758A (en) Anti-nkg2a antibodies and uses thereof
JP2023080187A (ja) 増強されたキメラ抗原受容体およびその使用
Nguyen et al. HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2023001962A (es) Composiciones anti-cd28.
Gunda et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
Bezman et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
ZA202301445B (en) Proteins binding nkg2d, cd16 and egfr
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
EP4588484A3 (en) Methods of treating multiple myeloma
MX2024003993A (es) Proteinas que se unen al miembro d del grupo 2 de asesinos naturales (nkg2d), cumulo de diferenciacion 16(cd16) y receptor del factor activador de celulas b (baff-r).
PH12020500664A1 (en) C3-binding agents and methods of use thereof
WO2021183675A3 (en) Methods for generating engineered memory-like nk cells and compositions thereof
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
WO2024178202A3 (en) Anti-cd3 antibodies and methods for their use
WO2024227174A3 (en) Antibodies that bind ox40l and methods of use
PH12022553153A1 (en) Binding molecules for the treatment of cancer
JOP20250032A1 (ar) بروتينات ترتبط ب nkg2d، cd16، وceacam5
MX2025006929A (es) Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos